Discussion:
Cytopenias are known side effects of many multiple myeloma drugs. Thrombocytopenia being
reported in up to 14.7% of patients on treatment with Lenolidomide, 69% on belantamab mafodotin-blmf,
32% on Carfilzomib. This case represents the challenges in treating relapsed myeloma patients
with persistent cytopenia and hemorrhaging. Often, as in this case, frequent transfusions and
disruption of treatment are required. Recurrent episodes of radiation therapy for extramedullary
relapse provided some benefit. Novel agents such as belantamab mafodotin-blmf may have a role in
treating extrameduallry disease.
